Kynexis
North Holland, Netherlands · Biotechnology, Health Care, Therapeutics
Kynexis is a clinical-stage biotechnology company focused on improving cognition for people living with brain diseases. The company is advancing KYN-5356, a potential first-in-class investigational medicine aimed at treating cognitive impairment associated with schizophrenia. Kynexis aims to address cognitive dysfunction across multiple neurological and neurodegenerative disorders. The company is
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- North Holland, Netherlands
- Employees
- 21
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- kynexis.io
- Company page
Recent activity at Kynexis
About Kynexis: questions and answers
What does Kynexis do?
Kynexis is a clinical-stage biotechnology company focused on improving cognition for people living with brain diseases. The company is advancing KYN-5356, a potential first-in-class investigational medicine aimed at treating cognitive impairment associated with schizophrenia. Kynexis aims to address cognitive dysfunction across multiple neurological and neurodegenerative disorders. The company is
Where is Kynexis headquartered?
Kynexis is headquartered in North Holland, Netherlands.
How many employees does Kynexis have?
Kynexis has about 21 employees.
What is the latest news on Kynexis?
On Aug 19, 2026, Kynexis extends its Series A funding by €40 million, bringing the total to €97 million. The funding, led by Novartis Venture Fund, will support Phase 2 studies for its cognitive medicine.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy